This knowledge could help us to design more effective strategies to treat AD by targeting the IFN response or its downstream effector CXCL10 that are upstream of myelination deficits, an early event in AD pathogenesis that proceeds before cognitive decline. The gene discussed is CXCL10; the disease is Alzheimer disease.